JP2023505279A5 - - Google Patents

Info

Publication number
JP2023505279A5
JP2023505279A5 JP2022533664A JP2022533664A JP2023505279A5 JP 2023505279 A5 JP2023505279 A5 JP 2023505279A5 JP 2022533664 A JP2022533664 A JP 2022533664A JP 2022533664 A JP2022533664 A JP 2022533664A JP 2023505279 A5 JP2023505279 A5 JP 2023505279A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
seq
product according
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505279A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063339 external-priority patent/WO2021113655A1/en
Publication of JP2023505279A publication Critical patent/JP2023505279A/ja
Publication of JP2023505279A5 publication Critical patent/JP2023505279A5/ja
Pending legal-status Critical Current

Links

JP2022533664A 2019-12-05 2020-12-04 抗trem2抗体の使用方法 Pending JP2023505279A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944298P 2019-12-05 2019-12-05
US62/944,298 2019-12-05
US202063005110P 2020-04-03 2020-04-03
US63/005,110 2020-04-03
PCT/US2020/063339 WO2021113655A1 (en) 2019-12-05 2020-12-04 Methods of use of anti-trem2 antibodies

Publications (2)

Publication Number Publication Date
JP2023505279A JP2023505279A (ja) 2023-02-08
JP2023505279A5 true JP2023505279A5 (https=) 2023-12-12

Family

ID=74046174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533664A Pending JP2023505279A (ja) 2019-12-05 2020-12-04 抗trem2抗体の使用方法

Country Status (10)

Country Link
US (1) US20230024528A1 (https=)
EP (1) EP3986937A1 (https=)
JP (1) JP2023505279A (https=)
KR (1) KR20220110537A (https=)
CN (1) CN115003699A (https=)
AU (1) AU2020397888A1 (https=)
CA (1) CA3158565A1 (https=)
IL (1) IL293386A (https=)
MX (1) MX2022006073A (https=)
WO (1) WO2021113655A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JP7745557B2 (ja) * 2020-02-24 2025-09-29 アレクトル エルエルシー 抗trem2抗体の使用方法
IL296992A (en) * 2020-04-03 2022-12-01 Alector Llc Methods for using anti-trem2 antibodies
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
AU2023373911A1 (en) * 2022-11-01 2025-05-15 Andreas Meier Anti-trem2 antibody and uses thereof
WO2025030887A1 (zh) * 2023-08-09 2025-02-13 成都优洛生物科技有限公司 抗trem2纳米抗体或其抗原结合片段及应用
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025215252A1 (en) * 2024-04-12 2025-10-16 Ensocell Ltd Therapeutic agents and methods for targeting myeloid cell subtypes

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20190330335A1 (en) 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
CN109641961A (zh) * 2016-07-22 2019-04-16 德国神经退行性疾病研究中心 Trem2切割调节剂及其用途
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
DK3601358T5 (da) 2017-08-03 2024-09-02 Alector Llc Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
IL296992A (en) * 2020-04-03 2022-12-01 Alector Llc Methods for using anti-trem2 antibodies
JP2023536916A (ja) 2020-08-05 2023-08-30 ビジル・ニューロサイエンス・インコーポレイテッド Trem2アゴニストを使用した、コロニー刺激因子1受容体機能不全に関連する疾患の治療

Similar Documents

Publication Publication Date Title
JP2023505279A5 (https=)
JP7306660B2 (ja) RGMa結合タンパク質及びその使用
US20210040188A1 (en) Humanized Antibodies That Recognize Alpha-Synuclein
JP2023029882A (ja) 抗trem2抗体及びその使用方法
US8398972B2 (en) Methods of treating dementia using a GM-CSF antagonist
JP2018537956A5 (https=)
IL300327A (en) Treatment of diseases associated with colony-stimulating factor receptor 1 dysfunction using TREM2 agonists
JP2022536613A5 (https=)
JP2022513075A (ja) タウオパチーの処置のための、タウペプチド抗原およびそれに結合する抗体
EP3638694A1 (en) Compositions and methods for treating tauopathies
TW202019481A (zh) 末稍神經障礙或伴隨著觀察到末稍神經障礙或星狀細胞障礙之疾病的疼痛之預防或治療方法
JP2023515478A5 (https=)
CA3161206A1 (en) Methods of use of anti-cd33 antibodies
US20210347869A1 (en) Methods and compositions for treating tauopathies
US20230101618A1 (en) Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
JP7610767B2 (ja) レット症候群の処置のためのセマフォリン4d結合分子の使用
WO2023081898A1 (en) Soluble cd33 as a biomarker for anti-cd33 efficacy
US20250177565A1 (en) Methods and materials for inhibiting/preventing the trafficking of monocytes to the central nervous system
WO2010093814A1 (en) Methods of treating dementia using a gm-csf antagonist
JP2024535403A (ja) 神経変性障害を処置するための抗セマフォリン4d結合分子の使用に関する予測アウトカムプロファイリング
RU2575629C2 (ru) Гуманизированные антитела, которые распознают альфа-синуклеин
WO2023064942A1 (en) Methods of suppressing microglial activation
HK1261629B (en) Humanized antibodies that recognize alpha-synuclein
CN108473576A (zh) 用于治疗复发形式的多发性硬化的方法
HK1201450B (en) Humanized antibodies that recognize alpha-synuclein